Literature DB >> 33713232

Expression and Clinical Significance of OX40 and OX40L mRNA in Hepatocellular Carcinoma.

P Du1, Z Wang2, J Geng3, Y Wang4.   

Abstract

In a retrospective study, the expression of mRNA of membrane receptor OX40 and its ligand OX40L in liver tissues was analyzed in 34 patients with hepatocellular carcinoma in order to assess their clinical implications and prognostic value. Expression of mRNA was analyzed by reverse transcription PCR and TaqMan probes. Expression of OX40 mRNA was significantly higher in tumor specimens in paired comparison with the samples of adjacent non-tumor tissue or normal liver tissue of control patients. In contrast, expression of OX40L mRNA was lower in tumor tissue in paired comparison with the samples of adjacent non-tumor tissue or normal liver tissue. The clinical and pathological analysis showed that expression of OX40 mRNA significantly correlated with the degree of tumor differentiation; there was an insignificant decreasing trend in the length of recurrence-free period. It was hypothesized that microenvironment of hepatocellular carcinoma can induce immunosuppression due to dysregulation of the expression of OX40 and OX40L in tumor tissue, which promotes tumor growth.

Entities:  

Keywords:  OX40; OX40L; hepatocellular carcinoma; mRNA expression; prognostic value

Year:  2021        PMID: 33713232     DOI: 10.1007/s10517-021-05093-8

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  13 in total

1.  Activin A expression in esophageal carcinoma and its association with tumor aggressiveness and differentiation.

Authors:  Zhenhua Wang; Ning Zhang; Ruifeng Song; Ruitai Fan; Liuqin Yang; Liping Wu
Journal:  Oncol Lett       Date:  2015-05-20       Impact factor: 2.967

2.  Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer.

Authors:  Needa A Virani; Elangovan Thavathiru; Patrick McKernan; Kathleen Moore; Doris M Benbrook; Roger G Harrison
Journal:  Cancer Lett       Date:  2018-03-21       Impact factor: 8.679

Review 3.  Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease.

Authors:  John Attanasio; E John Wherry
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

4.  ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection.

Authors:  Todd C Metzger; Hua Long; Shobha Potluri; Thomas Pertel; Samantha L Bailey-Bucktrout; John C Lin; Tihui Fu; Padmanee Sharma; James P Allison; Reid M R Feldman
Journal:  Cancer Res       Date:  2016-05-04       Impact factor: 12.701

Review 5.  The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy.

Authors:  Sarah L Buchan; Anne Rogel; Aymen Al-Shamkhani
Journal:  Blood       Date:  2017-11-08       Impact factor: 22.113

6.  Cancer statistics in China, 2015.

Authors:  Wanqing Chen; Rongshou Zheng; Peter D Baade; Siwei Zhang; Hongmei Zeng; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  CA Cancer J Clin       Date:  2016-01-25       Impact factor: 508.702

Review 7.  Rationale for anti-OX40 cancer immunotherapy.

Authors:  Sandrine Aspeslagh; Sophie Postel-Vinay; Sylvie Rusakiewicz; Jean-Charles Soria; Laurence Zitvogel; Aurélien Marabelle
Journal:  Eur J Cancer       Date:  2015-11-30       Impact factor: 9.162

8.  OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers.

Authors:  Yayi He; Xiaoshen Zhang; Keyi Jia; Rafal Dziadziuszko; Sha Zhao; Juan Deng; Hao Wang; Fred R Hirsch; Caicun Zhou
Journal:  Transl Lung Cancer Res       Date:  2019-08

9.  OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer.

Authors:  Juan Deng; Sha Zhao; Xiaoshen Zhang; Keyi Jia; Hao Wang; Caicun Zhou; Yayi He
Journal:  Onco Targets Ther       Date:  2019-09-06       Impact factor: 4.147

Review 10.  OX40, OX40L and Autoimmunity: a Comprehensive Review.

Authors:  Gwilym J Webb; Gideon M Hirschfield; Peter J L Lane
Journal:  Clin Rev Allergy Immunol       Date:  2016-06       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.